Business Wire

BOOST.AI

11.5.2023 09:02:35 CEST | Business Wire | Press release

Share
Boost.ai Unveils Large Language Model Enhancements to Conversational AI Platform

Boost.ai, a leading conversational AI solution provider, today announced Version 12 of its platform, the first of a series of planned updates by the company to incorporate Large Language Model (LLM)-enriched features. This iteration is focused on key customer experience (CX) improvements, including content suggestion, content rewriting and accelerated generation of training data. The new update will take advantage of Generative AI to suggest messaging content to AI Trainers within the boost.ai platform, generating suggested responses and resulting in drastically reduced implementation times for new intents. With this latest release, boost.ai reinforces its commitment to researching, developing, releasing, and maintaining responsible implementations of LLM-powered, enterprise-quality conversational AI features in order to further enhance the customer experience.

ChatGPT has dominated headlines throughout 2023, yet questions about the accuracy of its underlying models, GPT-3.5 and GPT-4, persist. With an 85% accuracy rate, LLMs are a good indication of the potential of this technology in consumer-facing applications, but in their current raw state they lack the dependency for integration directly into a bank or insurance firm's systems. Boost.ai helps to resolve this issue by seamlessly integrating the predictive capabilities of LLMs with enterprise-grade control of their conversational AI platform, creating a Hybrid Natural Language Understanding (NLU) system that offers unmatched accuracy, flexibility, and cost-effectiveness. Expertly weaving together the right AI components for each task, boost.ai’s platform ensures precise and accurate answers - harnessing the benefits of LLMs, while still adhering to stringent quality assurance requirements.

“LLM technology offers great promise, but most applications just aren’t properly designed to securely and scalably support real-world businesses. With worries about accuracy or even inappropriate behavior, established institutions like banks could not risk direct access to this iteration of generative AI - until now,” said Jerry Haywood, CEO of boost.ai. “By pairing LLMs with our conversational AI, we’re able to ensure accuracy and open the door for customers in sensitive industries like financial services. We’re proud to be pioneering a way forward for businesses to harness this tech right now. It’s available for customers to use and enhance their existing solution, and to help them achieve speed to value significantly sooner whilst minimizing the risks currently dominating headlines.”

With a Hybrid NLU approach, enterprises gain the ability to combine boost.ai’s market-leading intent management, context handling, and dialogue management solutions with powerful LLM-enriched tools. Boost.ai’s existing intent engine is highly trained with guardrails in place to help guide the LLM, increasing overall accuracy and reducing the number of false positives. The end result is a chatbot that can confidently provide answers to inquiries, and a more streamlined development path that radically enhances how boost.ai customers can build scalable customer experiences for chat and voice.

“With our Hybrid NLU, we’ve been able to surpass the performance of either model on its own, providing our customers with the best of both worlds,” said Lars Ropeid Selsås, Founder of boost.ai. “Boost.ai will continue to operate at the cutting edge of AI possibility, refining our platform so that our customers are always receiving the best possible technology and service.”

On May 9th, Boost.ai co-founder, Henry Vaage Iversen and the technical team conducted a webinar highlighting the strengths of Hybrid NLU and mapping out a path for businesses to start using LLM technology to their advantage. For a recording of the full webinar, please visit: https://www.boost.ai/webinars/enhancing-cx-and-reducing-operational-costs-with-boost-ai-large-language-models

About Boost.ai

Boost.ai is a global leader in conversational AI optimized for scale. Boasting the industry's most robust intent portfolio, Boost.ai is pioneering an era of broad-scope virtual agents to deliver the most advanced and scalable technology on the market. With consistent resolution rates of 90%, Boost.ai’s market-leading virtual agent supports enterprise customers across key industries throughout the United States and Europe, including banking, insurance, telecom, retail and more. In 2021, Boost.ai was named a major player in the IDC MarketScape category, Worldwide Conversational AI Platforms for Customer Service. Key customers include Santander Bank, MSU Federal Credit Union, Aspire General Services, Tokio Marine and more. Learn more at boost.ai.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005082/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye